Table 3. Screening for advanced liver fibrosis (LSM ≥8.0 kPa) using non-invasive fibrosis tests in patients with a valid Fibroscan.
| Tests | N | Cut-off | Se % (95% CI) | Spe % (95% CI) | PPV % (95% CI) | NPV % (95% CI) | Accuracy % | AUROCs (95% CI) | Patients with suspected AdLF on NITs&, n (%) | LSM ≥ 8 kPa among H-I NITs&, n (%) |
|---|---|---|---|---|---|---|---|---|---|---|
| NFS | 187 | ≥-1.455/0.12† | 70.0 (39.7–89.2) | 63.3 (55.9–70.0) | 9.7 (5.5–13.9) | 97.4 (95.1–99.7) | 63.6 (60.1–67.2) | 0.686 (0.466–0.826) | 72 (38.5) | 7 (9.7) |
| Forns | 189 | ≥4.2 | 100 (72.2–100) | 16.2 (11.5–22.3) | 6.2 (2.7–9.7) | 100 (1–1) | 20.6 (17.6–23.5) | 0.728 (0.536–0.848) | 160 (84.6) | 10 (6.2) |
| APRI | 188 | ≥0.5 | 30.0 (10.8–60.3) | 91.0 (85.9–94.4) | 15.8 (10.6–21.0) | 95.8 (92.9–98.6) | 87.7 (85.3–90.1) | 0.678 (0.386–0.846) | 19 (10.1) | 3 (15.8) |
| FIB-4 | 188 | ≥1.30/2.0† | 20.0 (5.7–51.0) | 74.2 (67.3–80.0) | 4.2 (1.3–7.1) | 94.3 (91.0–97.6) | 71.3 (68.0–74.6) | 0.647 (0.473–0.772) | 48 (25.5) | 2 (4.2) |
| eLIFT | 189 | ≥8 | 60.0 (31.3–83.2) | 70.4 (63.3–76.6) | 10.2 (5.9–14.5) | 96.9 (94.4–99.4) | 69.8 (66.5–73.1) | 0.739 (0.543–0.858) | 59 (31.2) | 6 (10.2) |
&: High and intermediate zones (H-I zones) of NFS, APRI, Forns and FIB-4 were grouped; patients in the H-I zones and those with eLIFT ≥ 8 had suspected AdLF and were referred for liver stiffness measurement (LSM).
†: First cut-off for patients aged < 65 years, second cut-off for patients aged ≥65 years.
NITs, non-invasive fibrosis tests.